Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
- This new finding may help in developing treatment for age-related macular degenerationon October 17, 2019 at 7:30 am
A team of scientists has unraveled the molecular mechanism behind the development of age-related macular degeneration (AMD). It has found that it develops because of abnormal activity of a set of ...
- Macular Degeneration Treatment Market Trends, Forecast and Competitive Analysison October 16, 2019 at 11:19 pm
Oct 17, 2019 (Market Prediction via COMTEX) -- According to ARC’s latest market research report, The global Macular Degeneration Treatment Market worth $11.4 billion by 2026 and growing CAGR around ...
- Gene-Therapy Treatment May Help People with Macular Degenerationon October 16, 2019 at 3:33 pm
Age-related macular degeneration (AMD) is one of the leading causes of vision loss and blindness among older adults in the United States. But now researchers are looking at a potential new treatment ...
- New drug gives 'stunning' improvement with dry macular degenerationon October 15, 2019 at 2:33 pm
There's new hope for adults with blurry vision due to "dry" macular degeneration. Patients given a new drug as part of a clinical trial were able to see eight more letters clearly on the vision chart ...
- Gene therapy effective for treating wet age-related macular degeneration: Studyon October 14, 2019 at 11:16 pm
Recently developed gene therapy seems to be a promising alternative for treating one of the most common causes of blindness, wet age-related macular degeneration (AMD), claims a study. Researchers ...
- Gene therapy effective for treating macular degeneration: Studyon October 14, 2019 at 6:26 am
Shutterstock. Recently developed gene therapy seems to be a promising alternative for treating one of the most common causes of blindness, wet age-related macular degeneration (AMD), claims a study.
- Gene Therapy Will be Available Soon for Age-related Macular Degenerationon October 14, 2019 at 5:29 am
Gene therapy may be the answer to one of the most common causes of blindness, wet age-related macular degeneration (AMD). Gene therapy is showing promise for one of the most common causes of blindness ...
- In-office gene therapy for wet age-related macular degeneration is comingon October 11, 2019 at 9:03 am
Gene therapy is showing promise for one of the most common causes of blindness. Data presented today shows that six patients with wet age-related macular degeneration (AMD) have, so far, gone at least ...
- Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degenerationon October 10, 2019 at 5:11 pm
Kodiak's lead product candidate, KSI-301, is a novel anti-VEGF antibody biopolymer conjugate being developed for the treatment of retinal vascular diseases including age-related macular degeneration ...
- Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomeson October 8, 2019 at 2:38 pm
Repeated intravitreal injections of anti-vascular endothelial growth factor-A (VEGF) pharmaceuticals are the cornerstone of neovascular age-related macular degeneration (nAMD) management. 1–4 Multiple ...
via Google News and Bing News